TABLE 1.
Baseline Characteristics of ADMET 2 Participants Included in Analyses
| Factor | Overall (N = 177) | Methylphenidate (n = 88) | Placebo (n = 89) | t/χ2 (df), p |
|---|---|---|---|---|
|
| ||||
| Age (years), mean (SD) | 76.0 (7.8) | 76.4 (8.2) | 75.7 (7.5) | −0.88(175), 0.54 |
| Sex, n (%) | ||||
| Female | 59 (33.3) | 29 (33.0) | 30 (33.7) | <0.01 (1), 0.99 |
| Male | 118 (66.7) | 59 (67.0) | 59 (66.3) | |
| Education, n (%) | ||||
| HS or less | 45 (25.4) | 23 (26.1) | 22 (24.7) | 0.80 (3), 0.85 |
| Some college | 37 (20.9) | 16 (18.2) | 21 (23.6) | |
| Bachelor’s degree | 51 (28.8) | 26 (29.5) | 25 (28.1) | |
| Graduate/professional | 44 (24.9) | 23 (26.1) | 21 (23.6) | |
| Medications, n (%) | ||||
| Memantine | 63 (35.6) | 33 (37.5) | 30 (33.7) | 0.14 (1), 0.71 |
| Cholinesterase inhibitors | 131 (74.0) | 68 (77.3) | 63 (70.8) | 0.66 (1), 0.42 |
| SSRI | 63 (35.6) | 29 (33.0) | 34 (38.2) | 0.33 (1), 0.57 |
| SNRI | 11 (6.2) | 6 (6.8) | 5 (5.6) | <0.01 (1), 0.98 |
| Any AD medications | 141 (79.7) | 71 (80.7) | 70 (78.7) | 0.02 (1), 0.88 |
| Baseline NPI-A severity, n (%) | ||||
| Mild | 20 (11.3) | 10 (11.4) | 10 (11.2) | 1.40 (2), 0.50 |
| Moderate | 121 (68.4) | 57 (64.8) | 64 (71.9) | |
| Marked | 36 (20.3) | 21 (23.9) | 15 (16.9) | |
| Baseline blood pressure, mean (SD) | ||||
| Systolic | 136.3 (17.7) | 135.6 (18.2) | 137.0 (17.2) | 0.49 (175), 0.62 |
| Diastolic | 75.9 (10.0) | 76.4 (9.6) | 75.5 (10.3) | −0.57 (175), 0.57 |
| Baseline NPI score, mean (SD) | ||||
| Agitation | 0.8(1.3) | 0.9(1.4) | 0.7(1.2) | −0.86 (175),0.39 |
| Anxiety | 1.1(2.2) | 0.8(1.5) | 1.4(2.6) | 2.1(175),0.04a |
| Apathy | 7.9 (2.3) | 8.0 (2.4) | 7.7 (2.2) | −0.70 (175), 0.48 |
| Depression | 0.9 (1.5) | 0.8 (1.5) | 1.0 (1.5) | 0.71 (175), 0.48 |
| Disinhibition | 0.6 (1.5) | 0.4 (1.0) | 0.8 (1.9) | 1.8 (174), 0.07 |
| Irritability | 1.2 (2.1) | 1.2 (1.9) | 1.2 (2.3) | −0.2 (175), 0.82 |
| Motor | 1.1 (2.5) | 0.9 (1.8) | 1.4 (3.0) | 1.2 (175), 0.22 |
| Sleep | 1.5 (2.9) | 1.2 (2.3) | 1.6 (3.4) | 1.3 (175), 0.21 |
| Total NPI | 16.7 (10.0) | 15.6 (7.5) | 17.7 (11.9) | 1.44 (175), 0.15 |
| Baseline cognition and function, mean (SD) | ||||
| Digit span forward | 8.2 (2.4) | 8.2 (2.3) | 8.1 (2.4) | −0.04 (174), 0.97 |
| MMSE | 19.3 (4.8) | 19.6 (4.6) | 19.0 (5.0) | −0.88 (175), 0.38 |
| ADCS-ADL | 52.2 (14.0) | 53.2 (14.3) | 51.1 (13.6) | −1.03 (175), 0.31 |
Notes: Predictors were selected based on a prespecified difference of greater than or equal to two points between categories of each predictor. t/χ2 represent Student’s t-test or χ2 test for continuous and categorical variables, respectively. AD: Alzheimer’s Disease; SSRI: selective serotonin reuptake inhibitors; SNRI: serotonin and norepinephrine reuptake inhibitors; NPI: neuropsychiatric inventory; MMSE: mini mental state examination; ADCS-ADL: Alzheimer’s Disease Cooperative Scale-Activities of Daily Living; HS: high school; df: degrees of freedom.
a
p<0.05.